In　order　to　develop　the　HIV　integrate　inhibitors　with　high　bioactivity　low　toxicity　and　favorable　bioavailability,　several　key　DKAs　(Diketo　acids)　integrate　inhibitors　are　introduced　to　provide　academic　basis　for　searching　effective　anti-HIV　medicine　according　to　those　medicines　widely　used　in　market.　Many　aspects　are　analyzed,　such　as　the　data　of　biological　activities,　pharmacophore,　target　design　and　clinic　research.　Further　R　and　D　direction　is　discussed,　which　can　be　references　for　developing　Diketo　acids　inhibitors　of　HIV　integrate.